Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 8,332 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Clear all
Completed Phase 2 Interventional

A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects

NCT00162305
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BMS-512148, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Miami, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 24, 2026, 10:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Insulin Sensitivity Using Aerobic Interval Conditioning

NCT01286922
View directory record Official record
Conditions
Pre-diabetes
Interventions
Behavioral: exercise
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
30 Years to 60 Years · Male only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Oct 24, 2026, 10:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects

NCT03970122
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GFB-887, Placebo
Drug
Lead sponsor
Goldfinch Bio, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2020 · Synced Oct 24, 2026, 10:24 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Effect of C-peptide on Hypoglycemic Counterregulation

NCT06470295
View directory record Official record
Conditions
Hypoglycemia, Type 1 Diabetes
Interventions
Saline, C-peptide
Other · Biological
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 40 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 24, 2026, 10:24 PM EDT
Recruiting No phase listed Observational

Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics

NCT06401577
View directory record Official record
Conditions
Acute Pancreatitis
Interventions
Dexcom Continuous Glucose Monitor (CGM)
Device
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Los Angeles, California • Stanford, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 24, 2026, 10:24 PM EDT
Completed Not applicable Interventional

Internet Diabetes Self-Management Workshop

NCT00185601
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Internet Diabetes Self-Management Program
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
761 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2013 · Synced Oct 24, 2026, 10:24 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

NCT02787551
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
74
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 24, 2026, 10:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

REAL HEALTH-Diabetes: Reach Ahead for Lifestyle and Health-Diabetes

NCT02320253
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
In Person Group (IP), Telephone Conference Call Group (TCC), Medical Nutrition Therapy (MNT)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
4
States / cities
Boston, Massachusetts • Charlestown, Massachusetts • Chelsea, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Oct 24, 2026, 10:24 PM EDT
Completed Phase 2 Interventional

Islet Cell Transplantation Alone and CD34+ Enriched Bone Marrow Cell Infusion in Patients With Diabetes Mellitus: Steroid-Free Regimen

NCT00021801
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Islet Cell Transplantation
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 24, 2026, 10:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Dose Safety Tolerability, Pharmacokinetics And Midazolam Interaction In Healthy Overweight And Obese Subjects

NCT01807377
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
PF-05175157, Midazolam, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 24, 2026, 10:24 PM EDT
Recruiting Not applicable Interventional

A Low-Carb Approach to Treat Type 2 Diabetes in Pediatric Patients

NCT06902077
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
low carb diet, diabetic diet
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
12 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 24, 2026, 10:24 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.

NCT00727857
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone and metformin, Pioglitazone, Metformin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
66
States / cities
Birmingham, Alabama • Haleyville, Alabama • Montgomery, Alabama + 63 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2011 · Synced Oct 24, 2026, 10:24 PM EDT
Recruiting Not applicable Interventional

Family Intervention for Black Teens With Type 1 Diabetes

NCT06275412
View directory record Official record
Conditions
Type 1 Diabetes, Family Relations
Interventions
The 3Ms 2.0 Intervention, Educational Attention Control (EAC)
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
10 Years to 14 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Detroit, Michigan • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 24, 2026, 10:24 PM EDT
Completed Not applicable Interventional

Evaluation of the Dexcom G6 Continuous Glucose Monitoring System With a Non-Interferent Sensor

NCT03087877
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Acetaminophen Challenge (G6 CGM)
Device
Lead sponsor
DexCom, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
4
States / cities
Escondido, California • Santa Barbara, California • Walnut Creek, California + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 24, 2026, 10:24 PM EDT
Completed No phase listed Observational

Pediatric Type 1 Diabetes and Retinopathy

NCT02691312
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Digital Retinography System
Device
Lead sponsor
University of Florida
Other
Eligibility
9 Years to 26 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
De Leon Springs, Florida • Gainesville, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 24, 2026, 10:24 PM EDT
Completed Not applicable Interventional Results available

Project to Improve Communication About Serious Illness--Hospital Study: Comparative Effectiveness Trial (Trial 2)

NCT04283994
View directory record Official record
Conditions
Dementia, Chronic Disease, Neoplasm Metastasis, Lung Neoplasms, Pulmonary Disease, Chronic Obstructive, Heart Failure, Congestive, Liver Cirrhosis, Kidney Failure, Chronic, Lung Diseases, Interstitial, Peripheral Vascular Disease, Diabetes With End Organ Injury
Interventions
Survey-based Patient/Clinician Jumpstart, EHR-based Clinician Jumpstart
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 24, 2026, 10:24 PM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus

NCT01952145
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
31
States / cities
Fresno, California • Los Alamitos, California • Palm Springs, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Oct 24, 2026, 10:24 PM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study of T0903131 (INT131) Besylate to Treat Type 2 Diabetes Mellitus

NCT00952445
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
T0903131 Besylate, Placebo
Drug
Lead sponsor
InteKrin Therapeutics, Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
21
States / cities
La Jolla, California • Los Angeles, California • Santa Ana, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Oct 24, 2026, 10:24 PM EDT
Withdrawn Phase 4 Interventional

Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary Angiography

NCT00335101
View directory record Official record
Conditions
Coronary Artery Disease (CAD), Renal Impairment, Diabetes Mellitus
Interventions
Iodixanol, Ioversol, Iopromide
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Oct 24, 2026, 10:24 PM EDT
Not listed Not applicable Interventional

Multi-component Intervention for Diabetes in Adults With Serious Mental Illness

NCT03627377
View directory record Official record
Conditions
Schizophrenia, Obesity, Diabetes, Lifestyle Risk Reduction, Serious Mental Illness
Interventions
Multi-component Intervention for Diabetes in Adults with Serious Mental Illness
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2021 · Synced Oct 24, 2026, 10:24 PM EDT
Completed Not applicable Interventional

Strengthening, Engaging, and Empowering Dyads Through Nutrition & Wellness

NCT06473129
View directory record Official record
Conditions
Diabetes, Memory Impairment
Interventions
Food for Life Culinary Workshops
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
65 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 24, 2026, 10:24 PM EDT
Terminated Not applicable Interventional

Effects of Mediterranean Diet Intervention in Diabetic Heart Disease

NCT03757845
View directory record Official record
Conditions
Diabetes Complications, Cardiovascular Diseases
Interventions
Mediterranean Diet
Other
Lead sponsor
MaineHealth
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Oct 24, 2026, 10:24 PM EDT
Terminated Phase 1 Interventional Results available

A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy

NCT01488877
View directory record Official record
Conditions
Type 2 Diabetic Nephropathy
Interventions
PF-03882845, Spironolactone, placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
6
States / cities
Chula Vista, California • San Diego, California • DeLand, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Oct 24, 2026, 10:24 PM EDT
Completed Not applicable Interventional Results available

Preservation of Pancreatic Beta Cell Function Through Insulin Pump Therapy

NCT00574405
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®]), CSII (Animas Corporation insulin pump, model IR 1200)
Drug · Device
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
8 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 24, 2026, 10:24 PM EDT